drugset / Trial / NCT03760042

Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements

NCT03760042

Phase 1 Completed 32 enrolled Pfizer
RandomizedParallel-groupTriple-blindOther

Summary

A double-blind within-subject study to estimate observed application site adverse events following topical applications of crisaborole and vehicle in healthy participants

Timeline

Start
2018-11-14
Primary completion
2019-04-15
Completion
2019-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Crisaborole Small molecule 2 % Topical

Indications

No indication recorded.